This clinical trial is evaluating an investigational vaccine designed to prevent chlamydia infections, a common sexually transmitted infection that often goes undetected due to lack of symptoms. The study aims to determine the safety of the investigational vaccine in adults aged 18 to 44 by comparing it with a placebo.
This vaccine could offer protection against initial infection and reinfection, potentially reducing the risk of serious health complications related to untreated chlamydia.
Study participation is approximately 18 months long and will require up to 16 in-person visits to our clinic, not including the 2 visits before vaccination, which will be done during our business hours of 9am-5pm, Monday- Friday. There will also be up to 5 phone calls over the 18-month period. Each participant will receive 3 doses of a vaccine for this study which will be given at Day 1, Month 2 and Month 6. Participants will be randomly assigned (by chance) to receive either the investigational vaccine or a placebo, with a 50% chance of receiving either. The study is blinded meaning participants will not know which study group they are in during their participation to avoid bias.
There will be several procedures done throughout the study, including a medical history collection, physical examination and vital signs measurement, ECGs, blood tests, pregnancy tests, urine tests and swab collections. Participants will also be asked to keep an eDiary.
Participants may be eligible if they:
Eligible participants will receive reimbursement for their time and study-related expenses.
